Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. - Pelletier M; Yang J; Joshi M; Grauel A; Abecunas C; Altzerinakou MA; Zhou Z; Zhu X; Clark K; Li L; Bai LY; Milella M; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026)